Second Sight Medical Products (EYES) - Get Report stock took off for a second straight trading day on Tuesday after the Food and Drug Administration approved the company's treatment of retinitis pigmentosa, better known as RP.
Second Sight stock was racking up more double-percentage-point gains following FDA approval last week of its Argus 2s hardware, glasses and video-processing unit that assists in offsetting the effects of the condition and helps restore eyesight.
RP is a rare genetic disorder that involves the breakdown and loss of cells in the retina of the eye. It causes vision loss that worsens over time and can eventually lead to blindness.
Watch the video above to learn more about how the technology works, and how investors view the Second Sight Medical's longer-term prospects.